ABUS Arbutus Biopharma Corporation

3.79
+0.04  (+1%)
Previous Close 3.75
Open 3.77
Price To Book 2.3
Market Cap 210258721
Shares 55,477,235
Volume 132,942
Short Ratio
Av. Daily Volume 190,108

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due 3Q 2019.
AB-452
Hepatitis B
Phase 1 trial to be completed 2Q 2019.
AB-506
Hepatitis B (HBV)
Phase 1 trial to be initiated 2Q 2019.
AB-729
Hepatitis B (HBV)